Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate

Biochemical and Biophysical Research Communications

Volumn 434, Issue 3, 2013, Pages 614-619

  Volpon, Laurent ^a   Osborne, Michael J ^a   Zahreddine, Hiba ^a   Romeo, Andrea A ^a   Borden, Katherine L B ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Drug design; Methyl 7 guanosine (m7G) cap; NMR; Ribavirin

Indexed keywords

INITIATION FACTOR 4E; RIBAVIRIN;

ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; NUCLEAR MAGNETIC RESONANCE;

EUKARYOTA;

EUKARYOTIC INITIATION FACTOR-4E; HUMANS; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; RIBAVIRIN;

MLCS; MLOWN;

EID: 84880498999     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.03.125     Document Type: Article

References (28)

1. K.L. Borden, B. Culjkovic-Kraljacic, Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?, Leuk Lymphoma 51 (2010) 1805-1815.
2. B. Culjkovic, K.L. Borden, Understanding and targeting the eukaryotic translation initiation factor eIF4E in head and neck cancer, J. Oncol. 2009 (2009) 981679.
3. W. Filipowicz, S.N. Bhattacharyya, N. Sonenberg, Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight?, Nat Rev. Genet. 9 (2008) 102-114.
4. J. Marcotrigiano, A.C. Gingras, N. Sonenberg, et al., Cocrystal structure of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP, Cell 89 (1997) 951-961.
5. K. Tomoo, Y. Matsushita, H. Fujisaki, et al., Structural basis for mRNA Cap-Binding regulation of eukaryotic initiation factor 4E by 4E-binding protein, studied by spectroscopic, X-ray crystal structural, and molecular dynamics simulation methods, Biochim. Biophys. Acta 1753 (2005) 191-208.
6. L. Volpon, M.J. Osborne, I. Topisirovic, et al., Cap-free structure of eIF4E suggests a basis for conformational regulation by its ligands, EMBO J. 25 (2006) 5138-5149.
7. N. Cohen, M. Sharma, A. Kentsis, et al., PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA, Embo J. 20 (2001) 4547-4559.
8. J.R. Graff, B.W. Konicek, T.M. Vincent, et al., Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity, J. Clin. Invest. 117 (2007) 2638-2648.
9. A. Kentsis, I. Topisirovic, B. Culjkovic, et al., Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap, Proc. Natl. Acad. Sci. USA 101 (2004) 18105-18110.
10. S. Assouline, B. Culjkovic, E. Cocolakis, et al., Molecular targeting of the oncogene eIF4E in AML: a proof-of-principle clinical trial with ribavirin, Blood 114 (2009) 257-260.
11. A. Kentsis, L. Volpon, I. Topisirovic, et al., Further evidence that ribavirin interacts with eIF4E, RNA 11 (2005) 1762-1766.
12. F. Pettersson, C. Yau, M.C. Dobocan, et al., Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer, Clin. Cancer. Res. 17 (2011) 2874-2884.
13. T. Page, J.D. Connor, The metabolism of ribavirin in erythrocytes and nucleated cells, Int. J. Biochem. 22 (1990) 379-383.
14. W.D. McCubbin, I. Edery, M. Altmann, et al., Circular dichroism and fluorescence studies on protein synthesis initiation factor eIF-4E and two mutant forms from the yeast Saccharomyces cerevisiae, J. Biol. Chem. 263 (1988) 17663-17671.
15. T. von Der Haar, P.D. Ball, J.E. McCarthy, Stabilization of eukaryotic initiation factor 4E binding to the mRNA 5′-Cap by domains of eIF4G, J. Biol. Chem. 275 (2000) 30551-30555.
16. S. Assouline, B. Kraljacic-Culjkovic, E. Cocolakis, et al., A Phase I combination study of ribavirin and low dose cytarabine arabinoside (ara-C) in M4/M5 acute myeloid leukemia (AML) and AML with high eIF4E, Blood (ASH Annual Meeting Abstracts) 118 (2011) 3606.
17. X. Chen, D.J. Kopecky, J. Mihalic, et al., Structure-guided design, synthesis, and evaluation of guanine-derived inhibitors of the eIF4E mRNA-cap interaction, J. Med. Chem. 55 (2012) 3837-3851.
18. C.J. Brown, I. McNae, P.M. Fischer, et al., Crystallographic and mass spectrometric characterisation of eIF4E with N7-alkylated cap derivatives, J. Mol. Biol. 372 (2007) 7-15.
19. A. Niedzwiecka, J. Marcotrigiano, J. Stepinski, et al., Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 50 cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins, J. Mol. Biol. 319 (2002) 615-635.
20. J. Marcotrigiano, A.C. Gingras, N. Sonenberg, et al., Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G, Mol. Cell 3 (1999) 707-716.
21. M. Ptushkina, T. von der Haar, M.M. Karim, et al., Repressor binding to a dorsal regulatory site traps human eIF4E in a high cap-affinity state, Embo J. 18 (1999) 4068-4075.
22. M. Ptushkina, T. von der Haar, S. Vasilescu, et al., Cooperative modulation by eIF4G of eIF4E-binding to the mRNA 5′ cap in yeast involves a site partially shared by p20, Embo J. 17 (1998) 4798-4808.
23. L. Volpon, M.J. Osborne, A.A. Capul, et al., Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E, Proc. Natl. Acad. Sci. USA 107 (2010) 5441-5446.
24. W. Saenger, Principles of Nucleic Acid Structure, Springer-Verlag, New York, 1984.
25. S.E. Carberry, E. Darzynkiewicz, J. Stepinski, et al., A spectroscopic study of the binding of N-7-substituted cap analogues to human protein synthesis initiation factor 4E, Biochemistry 29 (1990) 3337-3341.
26. W. Liu, M. Jankowska-Anyszka, K. Piecyk, et al., Structural basis for nematode eIF4E binding an m(2,2,7)G-Cap and its implications for translation initiation, Nucleic Acids Res. 39 (2011) 8820-8832.
27. M.J. Osborne, L. Volpon, J.A. Kornblatt, et al., EIF4E3 acts as a tumour suppressor by utilizing an atypical mode of methyl-7 guanosine cap recognition, Proc. Natl. Acad. Sci. USA (2013).
28. A. Fukuyo, Y. In, T. Ishida, et al., Structural scaffold for eIF4E binding selectivity of 4E-BP isoforms: crystal structure of eIF4E binding region of 4E-BP2 and its comparison with that of 4E-BP1, J. Pept. Sci. 17 (2011) 650-657.